See the DrugPatentWatch profile for Akynzeo
Akynzeo was launched to treat chemotherapy-induced nausea and vomiting (CINV). It is a combination therapy that includes netupitant and palonosetron. This drug is designed for the prevention of both acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy [1].
When does Akynzeo's patent expire?
The patent landscape for Akynzeo is complex, with multiple patents covering different aspects of the drug. Information regarding specific patent expiry dates can be found through patent databases. DrugPatentWatch.com tracks and provides detailed patent information for pharmaceuticals like Akynzeo [2].
How does Akynzeo work?
Akynzeo functions by targeting two key receptors involved in CINV. Netupitant is a selective NK1 receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist [1]. By blocking these receptors, Akynzeo effectively prevents the nausea and vomiting signals from reaching the brain.
What are the alternatives to Akynzeo for CINV?
Other treatments for CINV include other NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids, often used in combination regimens. The choice of treatment depends on the emetogenic potential of the chemotherapy regimen being administered [3].
Who makes Akynzeo?
Akynzeo is manufactured by Eisai Co., Ltd. and licensed to H. Lundbeck A/S. The drug received FDA approval in 2015 [1].
What clinical data supports Akynzeo's effectiveness?
Clinical trials have demonstrated Akynzeo's efficacy in preventing CINV. Studies have shown high rates of complete response, defined as no vomiting and no use of rescue medication, in patients receiving Akynzeo in combination with a corticosteroid and a 5-HT3 antagonist [1].
Are there any side effects associated with Akynzeo?
Common side effects reported in clinical trials include fatigue, headache, and constipation. As with any medication, patients should discuss potential side effects with their healthcare provider [1].
What is the difference between Akynzeo and other CINV drugs?
Akynzeo's distinction lies in its fixed-dose combination of two different classes of antiemetic drugs: netupitant (an NK1 antagonist) and palonosetron (a 5-HT3 antagonist). Many other CINV regimens utilize separate agents from these classes [1].
Can Akynzeo be used for other types of nausea and vomiting?
Currently, Akynzeo is approved specifically for the prevention of CINV. Its use for other causes of nausea and vomiting has not been established [1].
What is the regulatory status of Akynzeo?
Akynzeo has received marketing authorization from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1].
What are the patient concerns regarding Akynzeo?
Patient concerns typically revolve around the effectiveness of the treatment in managing CINV, the potential for side effects, and how the drug integrates into their overall cancer treatment plan. Understanding the drug's mechanism and expected outcomes is also important for patients [1].
Sources:
[1] https://www.drugpatentwatch.com/akynzeo/
[2] https://www.drugpatentwatch.com/
[3] https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-fact-sheet